Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval: Draft Guidance for Industry
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
January 21, 2026
January 20, 2026
06f37c31-445c-4690-8220-150703bde2bd
Related Documents
Master Protocols for Drug and Biological Product Development
Guidance DocumentDecember 21, 2023Center for Drug Evaluation and Research
Labeling for Biosimilar and Interchangeable Biosimilar Products
Guidance DocumentSeptember 18, 2023Center for Drug Evaluation and Research
Clinical Trial Considerations to Support Accelerated Approval of Oncology Therapeutics
Guidance DocumentMarch 24, 2023Office of the Commissioner
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox